Search results
25 lis 2023 · All adult patients who had confirmed diagnosis of pemphigus vulgaris or pemphigus foliaceus, experienced treatment with rituximab (RTX) and were finally subjected to a combination therapy with mycophenolate mofetil, dapsone, or methotrexate due to:
23 lis 2020 · In this article, we will review the signalment, clinical signs, histopathology and treatment outcome of pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus in dogs, cats and horses; where pertinent, we compare the animal diseases to their human homologue.
28 lis 2019 · There is evidence that the anti‐CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add?
Newer-generation anti-CD20 antibodies like rituximab are a safer alternative for treating patients with pemphigus vulgaris. This review introduces possibly safer alternatives to rituximab. This information can guide clinicians and researchers to developing and using these alternatives.
1 kwi 2017 · Introduction. Pemphigus, an autoimmune disease, was fatal before the era of corticosteroids. With the advent of steroids, mortality decreased but morbidity was present due to the side effects of high dose steroids. Newer drugs targeted at the molecular level are said to have fewer side effects and improved effectiveness. Aim.
19 maj 2021 · Rituximab is recommended as first-line therapy in patients with pemphigus, 3,4 but the comparison with mycophenolate mofetil, a first-line glucocorticoid-sparing agent, in the treatment of...
In patients with moderate-to-severe PV, rituximab plus short-term prednisone was more effective than prednisone alone. Patients treated with rituximab had less CS exposure and were less likely to experience severe or life-threatening CS-related AEs.
